CAMBRIDGE, Mass. & GAITHERSBURG, Md.–(BUSINESS WIRE)–Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced a clinical and commercial license agreement under which Vor will use MaxCyte’s Flow Electroporation® technology to produce eHSCs and initiate Investigational New Drug (IND)-enabling studies to accelerate its progress towards the clinic.
{iframe}https://www.businesswire.com/news/home/20191121005101/en/Vor-Biopharma-MaxCyte-Announce-Clinical-Commercial-License{/iframe}